Macrophage-synthesized ccl3 promotes breast cancer metastasis
AssigneeAlbert Einstein College of Medicine of Yeshiva University
InventorJeffrey W. Pollard
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.
Claims20
A method of inhibiting metastasis of a tumor in a subject, or of inhibiting progression in a subject of a primary tumor which requires macrophages for progression, comprising administering to the subject an amount of an inhibitor of CCL3 effective to inhibit metastasis of a tumor or inhibit progression of a primary tumor requiring macrophages for progression.
A method of inhibiting metastasis of a tumor in a subject, or of inhibiting progression in a subject of a primary tumor which requires macrophages for progression, comprising administering to the subject an amount of an antagonist of a CCR5 receptor or of an antagonist of a CCR1 receptor effective to inhibit metastasis of a tumor or inhibit progression of a primary tumor requiring macrophages for progression.
(canceled)
A method for identifying an agent as a candidate inhibitor of metastasis, the method comprising:
- contacting a preparation comprising the macrophage and CCL3 in the absence of the agent and under conditions permitting the CCL3 to activate the macrophage, and determining CCL3 activation of the macrophage,
- contacting a preparation comprising a macrophage and CCL3 under the conditions, and in the presence of the agent, and determining CCL3 activation of the macrophage,
- wherein a reduction in activation of the macrophage in the presence of the agent as compared to in the absence of the agent indicates that the agent is a candidate inhibitor of metastasis, and wherein no change in or an increase in activation of the macrophage in the presence of the agent as compared to in the absence of the agent does not indicate that the agent is a candidate inhibitor of metastasis.
(canceled)
20-23. (canceled)
Dependencies are inferred from the claim text.